Celltrion Accelerates Push to Become Global New‑Drug Company at BioUSA

South Korean biopharma firm Celltrion presented its growth strategy at BioUSA. The company emphasized accelerating its transformation into a global new‑drug entity. Representatives outlined recent developments in its pipeline. BioUSA provided a platform to engage with international partners. Celltrion’s ambitions were reported by 아시아경제. The firm seeks to expand its presence in worldwide markets. Efforts include advancing novel therapeutics and expanding manufacturing capacity. Stakeholders will monitor Celltrion’s progress toward its global objectives.